76
|
Treiyer A, Saar M, Kopper B, Kamradt J, Siemer S, Stöckle M. Cistectomía radical laparoscópica asistida por robot: evaluación de los resultados funcionales y oncológicos. Actas Urol Esp 2011. [DOI: 10.4321/s0210-48062011000300006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
77
|
Roos F, Rübben H, Stief C, Stöckle M, Thüroff J. [Surgical treatment for renal cell carcinoma]. Aktuelle Urol 2010; 41:252-6. [PMID: 20661841 DOI: 10.1055/s-0030-1247480] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Renal cell carcinoma is chemoresistent and radio-therapy so that surgical tumour excision of the tumor is the only potentially curative option, either as radical nephrectomy or as nephron sparing surgery. As a result of continuously improving radiological imaging modalities, renal tumours are nowadays detected incidentally at an asymptomatic stage in up to 75 %. The ten-year cancer-specific survival for organ-confined disease (T1, T2) after R0-excision is > 90 %. Moreover, locally extending renal tumours (T3) can be treated successfully with five-year survival rates of > 65 %. In case of tumours in a single kidney or synchronous bilateral tumours, good functional and oncological long-term results can be achieved by nephron sparing surgery (imperative indication). T1 renal cell cancer (tumour size < 7 cm ) should be treated by nephron sparing surgery, even if the contralateral kidney is normal, because since this nephron-sparing approach ensures maximal renal reserve in the long term follow up. Minimally invasive techniques offer treatment also for multi-morbide patients. Which approach is to be selected depends on size and location of the tumour as well as on indication (elective or imperative), age and general health of the patient and the surgeon's preference.
Collapse
|
78
|
Ohlmann CH, Markert E, Stöckle M, Dienes H, Engelmann U, Heidenreich A. Expression of EGFR and HER2/neu and absence of activating mutations in patients with castration-resistant prostate cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.4652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
79
|
Roos F, Rübben H, Stief C, Stöckle M, Thüroff J. Operative Therapie des Nierenzellkarzinoms. Dtsch Med Wochenschr 2010. [DOI: 10.1055/s-0030-1248656] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
80
|
Roos FC, Rübben H, Stief C, Stöckle M, Thüroff JW. [Surgical treatment for renal cell carcinoma]. Dtsch Med Wochenschr 2010; 135:245-9. [PMID: 20127609 DOI: 10.1055/s-0029-1244841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Renal cell carcinoma is chemoresistent and radio-therapy so that surgical tumour excision of the tumor is the only potentially curative option, either as radical nephrectomy or as nephron sparing surgery. As a result of continuously improving radiological imaging modalities, renal tumours are nowadays detected incidentally at an asymptomatic stage in up to 75 %. The ten-year cancer-specific survival for organ-confined disease (T1,T2) after R0-excision is > 90 %. Moreover, locally extending renal tumours (T3) can be treated successfully with five-year survival rates of > 65 %. In case of tumours in a single kidney or synchronous bilateral tumours, good functional and oncological long-term results can be achieved by nephron sparing surgery (imperative indication). T1 renal cell cancer (tumour size < 7 cm ) should be treated by nephron sparing surgery, even if the contralateral kidney is normal, because since this nephron-sparing approach ensures maximal renal reserve in the long term follow up. Minimally invasive techniques offer treatment also for multi-morbide patients. Which approach is to be selected depends on size and location of the tumour as well as on indication (elective or imperative), age and general health of the patient and the surgeon's preference.
Collapse
|
81
|
Ohlmann CH, Stöckle M. [What comes after docetaxel?]. Urologe A 2009; 49:64-8. [PMID: 19902169 DOI: 10.1007/s00120-009-2146-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Chemotherapy with docetaxel represents the standard first-line treatment in patients with castration-resistant prostate cancer (CRPC). In cases of progression after treatment with docetaxel no standard treatment recommendation exists since no treatment was able to show a survival benefit in clinical trials. This review focuses on available treatment options for patients with progressive CRPC and highlights promising treatments that are currently under investigation in clinical trials including abiraterone acetate and MDV3100.
Collapse
|
82
|
Stief C, Zaak D, Stöckle M, Studer U, Knuechel R, Rödel C, Sauer R, Rubben H. [Standards and perspectives in diagnosis and therapy of bladder carcinoma]. Urologe A 2009; 45 Suppl 4:90-6. [PMID: 16896761 DOI: 10.1007/s00120-006-1134-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
MESH Headings
- Administration, Intravesical
- Antineoplastic Agents/administration & dosage
- Carcinoma, Papillary/diagnosis
- Carcinoma, Papillary/mortality
- Carcinoma, Papillary/pathology
- Carcinoma, Papillary/therapy
- Carcinoma, Transitional Cell/diagnosis
- Carcinoma, Transitional Cell/mortality
- Carcinoma, Transitional Cell/pathology
- Carcinoma, Transitional Cell/therapy
- Combined Modality Therapy
- Cystectomy
- Cystoscopy
- Disease-Free Survival
- Germany
- Hematoporphyrin Photoradiation
- Humans
- Immunotherapy
- Neoplasm Staging
- Prognosis
- Quality Assurance, Health Care/standards
- Reference Standards
- Urinary Bladder/pathology
- Urinary Bladder Neoplasms/diagnosis
- Urinary Bladder Neoplasms/mortality
- Urinary Bladder Neoplasms/pathology
- Urinary Bladder Neoplasms/therapy
Collapse
|
83
|
Natale N, Kuhn S, Siemer S, Stöckle M, von Gontard A. Quality of life and self-esteem for children with urinary urge incontinence and voiding postponement. J Urol 2009; 182:692-8. [PMID: 19539323 DOI: 10.1016/j.juro.2009.04.033] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2008] [Indexed: 10/20/2022]
Abstract
PURPOSE Urge incontinence and voiding postponement are common subtypes of daytime wetting in children. We analyzed health related quality of life for children with urge incontinence and voiding postponement, and healthy controls at 2 centers. MATERIALS AND METHODS We examined a total of 49 consecutive children 5 to 13 years old who presented with urge incontinence (22) or voiding postponement (27), and 32 controls matched for age and sex. Health related and overall quality of life were measured with generic questionnaires, and self-esteem was measured with the Piers-Harris questionnaire. RESULTS Health related quality of life was significantly reduced in parent rating but not in child rating in the incontinent vs control group (total mean parent score 73 vs 78, child 76 vs 76). Children with voiding postponement have the lowest health related quality of life. Overall quality of life was significantly reduced in children with incontinence, while self-esteem did not differ. Children with externalizing disorders generally have the lowest health related and overall quality of life. CONCLUSIONS Health related and overall quality of life are useful constructs, and are reduced in children with daytime incontinence by parental rating. In comparison, children rate their quality of life as being higher. Quality of life is lowest with externalizing behavioral disorders, as in children with voiding postponement. Due to comorbid behavioral disturbances, children with voiding postponement often need additional assessment, counseling and treatment.
Collapse
|
84
|
Hoffman AC, Wild P, Gauler T, Leicht C, Bertz S, Danenberg KD, Danenberg PV, Stöhr R, Stöckle M, Lehmann J, Hartmann A. Correlation of multidrug-resistance gene (MDR1) expression levels and outcome to adjuvant cisplatin/MTX based chemotherapy in patients enrolled in the AUO-AB 05/95 phase III trial. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5026 Background: The human MDR1 gene encodes an integral membrane protein, P glycoprotein (Pgp), whose function is the energy dependent export of substances from the inside of cells, and from membranes, to the outside. MDR1 mRNA levels have been shown to influence metabolism of cancer drugs. We tested whether MDR1 gene expression is associated with outcome in patients with locally advanced bladder cancer. Methods: 221 formalin fixed paraffin embedded (FFPE) tumor samples from patients with locally advanced and/or lymph node-positive bladder cancer enrolled for adjuvant therapy in the AUO-AB 05/95 phase III trial (Lehmann et al, J Clin Oncol. 2005;23:4963–4974) were analyzed (110 pts treated with cisplatin/MTX, 101 pts treated with MTX, vinblastine, epirubicin, and cisplatin, M-VEC).FFPE tissues were dissected using laser-captured microdissection and analyzed for MDR1 and ERCC1 mRNA expression using a quantitative real-time RT-PCR method. Gene expression values (relative mRNA levels) are expressed as ratios between the target gene and internal reference gene (beta-actin). Results: MDR1 was significantly correlated to progression free and overall survival. We included tumor stage (pT), lymph node status (pN) and the blood vessel invasion along with the measured gene expression in a stepwise multivariate Cox proportional hazards regression model. The overall model fit had a significance level of p = 0.0001 (<0.05). The relative risk for shorter survival in patients with High MDR1 expression was 2.8. Regarding survival MDR1 was strongly associated to ERCC1 expression in patients with M-VEC treatment. Conclusions: These results suggest that MDR1 gene expression levels predict response and overall survival in patients with locally advanced urothelial cancer enrolled in AUO-AB 05/95. MDR1 gene expression levels may allow the selection of patients who benefit likely from adjuvant cisplatin/MTX based chemotherapy. Further studies are warranted to study this association. [Table: see text]
Collapse
|
85
|
Gauler T, Hoffman AC, Wild P, Leicht C, Bertz S, Danenberg KD, Stöhr R, Stöckle M, Eberhardt WE, Lehmann J, Hartmann A. Use of multidrug-resistance gene (MDR1) expression levels to predict outcome to adjuvant cisplatin/gemcitabine based chemotherapy in patients with with locally advanced urothelial cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e22081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e22081 Background: The human MDR1 gene encodes an integral membrane protein, P glycoprotein (Pgp), whose function is the energy dependent export of substances from the inside of cells, and from membranes, to the outside. MDR1 mRNA levels have been shown to influence metabolism of cancer drugs. We tested whether MDR1 gene expression is associated with outcome in patients with locally advanced bladder cancer. Methods: 43 formalin fixed paraffin embedded (FFPE) tumor samples from patients with locally advanced and/or lymph node-positive bladder cancer undergoing treatment with cisplatin/gemcitabine were analyzed.FFPE tissues were dissected using laser-captured microdissection and analyzed for MDR1 expression using a quantitative real- time RT-PCR method. Gene expression values (relative mRNA levels) are expressed as ratios between the target gene and internal reference gene (beta-actin). Results: MDR1 was significantly correlated to overall survival. We included tumor stage (pT), lymph node status (pN) and the blood vessel invasion along with the measured gene expression in a stepwise multivariate Cox proportional hazards regression model. The overall model fit had a significance level of p=0.04 (<0.05). The relative risk for shorter survival in patients with High MDR1 expression was 1.9. Conclusions: These results suggest that MDR1 gene expression levels predict response and overall survival in patients with locally advanced urothelial cancer. MDR1 gene expression levels may allow the selection of patients who benefit likely from adjuvant cisplatin/gemcitabine based chemotherapy. Further studies are warranted to study this association. [Table: see text]
Collapse
|
86
|
Aulitzky W, Aulitzky W, Ellerhorst J, Logothetis C, Gomahr A, Stöckle M, Thews O, Scheibenbogen C, Keilholz U, Huber C. Intermittent Low-Dose IFN Gamma Treatment for Metastatic Renal Cell Carcinoma: Analysis of Factors Predicting Clinical Response and Long-Term Survival. Oncol Res Treat 2009. [DOI: 10.1159/000218614] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
87
|
Suttmann H, Kamradt J, Becker F, Lehmann J, Stöckle M. [Extending the limits of lymphadenectomy during radical cystectomy: pitfalls in the interpretation of contemporary study results]. Urologe A 2009; 48:151-5. [PMID: 19169660 DOI: 10.1007/s00120-008-1902-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
The optimal extent of lymphadenectomy performed during radical cystectomy for transitional cell carcinoma of the bladder is currently under intensive debate. Extending the limits of lymphadenectomy has been hypothesized to add further diagnostic and therapeutic benefit. However, our current knowledge is based exclusively on results from retrospective studies that are hampered by several statistical shortcomings. This article provides a critical analysis of the contemporary data on the subject and outlines typical statistical pitfalls that must be considered when interpreting such research results.
Collapse
|
88
|
Ohlmann CH, Gasser T, Stöckle M. [Operative therapy of bladder carcinomas]. Urologe A 2009; 48:125-6. [PMID: 19156395 DOI: 10.1007/s00120-008-1930-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
89
|
Jung V, Saar M, Grobholz R, Stöckle M, Unteregger G, Kamradt J. [Development of a three-dimensional primary prostate cancer cell culture model]. Urologe A 2008; 47:1199-204. [PMID: 18682911 DOI: 10.1007/s00120-008-1835-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Much prostate cancer research is based on cell culture results. Recent genomic studies found major differences between primary prostate cancer tissue and established prostate cancer cell lines, which calls into question the clinical relevance of study results based on cell cultures.Using primary cultures of prostate cancer cells from prostatectomy specimens seems to be a reasonable solution, but primary cell cultures are much more difficult to establish. In this study, a primary cell culture model was combined with an invasion assay. With this combination it was possible not only to select invasive cell clones from the primary culture but also to culture these cells in a three-dimensional model, forming spheroids. A further characterization of this cell population was done by comparative genomic hybridization, showing numerous genetic alterations. The presented cell culture model offers, for the first time, an opportunity to isolate invasive growing cells from primary prostate cancer tissue and cultivate these cells for further analyses.
Collapse
|
90
|
Stöckle M, Störkel S, Mielke R, Steinbach F, Galler E, Riedmiller H, Hohenfellner R. Charakterisierung konservativ operierter Nierentumoren mit der automatisierten DNS-Bildzytometrie. Aktuelle Urol 2008. [DOI: 10.1055/s-2008-1060623] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
91
|
Stöckle M, Riedmiller H, Jacobi G, Hohenfellner R. Radikale Zystektomie beim älteren Patienten. Aktuelle Urol 2008. [DOI: 10.1055/s-2008-1061401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
92
|
Melchior S, Stöckle M, Voges G, Steinbach F, Hohenfellner R. Harnstauungsniere beim Blasenkarzinom - schlechte Prognose? Aktuelle Urol 2008. [DOI: 10.1055/s-2008-1060515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
93
|
Stöckle M, Meyenburg W, Wellek S, Voges G, Gertenbach U, Thüroff J, Huber C, Hohenfellner R. Fortgeschrittenes Blasenkarzinom (Stadien pT3b, pT4a, pN1, pN2). Aktuelle Urol 2008. [DOI: 10.1055/s-2008-1060502] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
94
|
Steinbach F, Jenny E, Müller S, Stöckle M, Perovic S, Beetz R, Hohenfellner R. Blasenekstrophie und artifizieller Sphinkter - Die Lösung der Probleme? Aktuelle Urol 2008. [DOI: 10.1055/s-2008-1060497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
95
|
Bier B, Seitz G, Becht E, Wagner A, Stöckle M, Remberger K. Häufigkeit von Karzinomen in der Prostata nach radikaler Zystoprostatektomie wegen eines Harnblasenkarzinoms - Eine klare Kontraindikation zum Belassen apikaler Prostatareste. Aktuelle Urol 2008. [DOI: 10.1055/s-2008-1060529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
96
|
Steinbach F, Stöckle M, Hohenfellner M, Schweden F, Riedmiller H, Hohenfellner R. Vaskulär bedingte Hämaturie. Aktuelle Urol 2008. [DOI: 10.1055/s-2008-1061234] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
97
|
Stöckle M, Alken P, Engelmann U, Jacobi G, Riedmiller H, Hohenfellner R. Radikale Zystektomie - Oft zu spät? Aktuelle Urol 2008. [DOI: 10.1055/s-2008-1061671] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
98
|
Stöckle M, Müller S, Riedmiller H. Pyonephrose durch Ischiadikushernie. Aktuelle Urol 2008. [DOI: 10.1055/s-2008-1061225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
99
|
Stöckle M. Therapie des Blasenkarzinoms - Quo vadis? Aktuelle Urol 2008. [DOI: 10.1055/s-2008-1060441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
100
|
Leiβner J, Störkel S, Stöckle M, Hohenfellner R. Der Amyloidtumor der Harnblase - eine seltene Ursache der Makrohämaturie. Aktuelle Urol 2008. [DOI: 10.1055/s-2008-1058306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|